A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar Mania
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The authors compared the efficacy and safety of aripiprazole, a novel antipsychotic, to placebo for treatment of patients in an acute manic or mixed episode of bipolar disorder. METHOD: This 3-week, multicenter, double-blind study randomly assigned 262 bipolar disorder patients in an acute manic or mixed episode to aripiprazole, 30 mg/day (reduced to 15 mg/day if needed for tolerability), or placebo. Patients remained hospitalized for at least 2 of the weeks. The primary efficacy measure was mean change from baseline in total score on the Young Mania Rating Scale; response was defined as a decrease in score of > or =50%. RESULTS: Aripiprazole produced statistically significant mean improvements in total score on the Young Mania Rating Scale compared with placebo (-8.2 versus -3.4, respectively) and produced a significantly higher response rate (40% versus 19%). For key efficacy variables (response per Young Mania Rating Scale; Clinical Global Impression-Bipolar Version scores for severity of illness [mania] and change from preceding phase [mania]), aripiprazole separated from placebo by day 4. The completion rate was significantly higher with aripiprazole than with placebo (42% versus 21%). Discontinuations due to adverse events did not differ significantly between the aripiprazole and placebo groups. There were no significant changes in body weight versus placebo, and aripiprazole was not associated with elevated serum prolactin or QTc prolongation. CONCLUSIONS: Aripiprazole had significantly greater efficacy than placebo for the treatment of bipolar disorder patients in acute manic or mixed episodes and was safe and well tolerated in this randomized controlled trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · cited 12×
“For key efficacy variables (response per Young Mania Rating Scale; Clinical Global Impression—Bipolar Version scores for severity of illness [mania] and change from preceding phase [mania]), aripiprazole separated from placebo by day 4.”
InfluentialA RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death
Glassman, A. H., & Bigger, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1774 · Cited by 822
Antipsychotic-induced weight gain: a review of the literature.
Allison, D. B., & Casey, D. E. (2001) · PubMed · Cited by 669
Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624
Self-citationOlanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Tohen, M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.9.841 · Cited by 539
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01532-7 · Cited by 512
Marder, S. R., McQuade, R. D., Stock, E., Kaplita, S., Marcus, R., Safferman, A. Z., Saha, A., Ali, M., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467
Self-citationKoro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R. (2002) · BMJ · doi:10.1136/bmj.325.7358.243 · Cited by 421 · cited 1×
“(9), hyperglycemia (10, 11), and dyslipidemia (12).”
Keck, P. E., Versiani, M., Potkin, S., West, S. A., Giller, E., Ice, K., & the Ziprasidone in Mania Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.741 · Cited by 369
Self-citationCorrelates of Overweight and Obesity in 644 Patients With Bipolar Disorder
McElroy, S. L., Frye, M. A., Suppes, T., Dhavale, D., Keck, P. E., Leverich, G. S., Altshuler, L., Denicoff, K. D., Nolen, W. A., Kupka, R., et al. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0306 · Cited by 334
Self-citationPrien, R. F. (1972) · Archives of General Psychiatry · doi:10.1001/archpsyc.1972.01750200050011 · Cited by 245
Prevalence of Obesity and Weight Change During Treatment in Patients With Bipolar I Disorder
Fagiolini, A., Frank, E., Houck, P. R., Mallinger, A. G., Swartz, H. A., Buysse, D. J., Ombao, H., & Kupfer, D. J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0611 · Cited by 202
Prevalence of Overweight and Obesity in Bipolar Patients
Elmslie, J. L., Silverstone, J. T., Mann, J. I., Williams, S. M., & Romans, S. E. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0306 · Cited by 193
Elevation of Prolactin Levels by Atypical Antipsychotics
Turrone, P., Kapur, S., Seeman, M. V., & Flint, A. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.133 · Cited by 190
Network interactions in schizophrenia — therapeutic implications
Carlsson, A. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00050-8 · Cited by 174
Novel Antipsychotics and Severe Hyperlipidemia
Meyer, J. M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00003 · Cited by 168
Atypical Antipsychotic???Induced Diabetes Mellitus: How Strong is the Evidence?
Henderson, D. C. (2002) · CNS Drugs · doi:10.2165/00023210-200216020-00001 · Cited by 162
Pharmacologic agents for the treatment of acute bipolar mania
McElroy, S. L., & Keck, P. E. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00961-6 · Cited by 160
Self-citationStahl, S. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1101 · Cited by 143
Stahl, S. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1201 · Cited by 135
A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania
Garfinkel, P. E., Stancer, H. C., & Persad, E. (1980) · Journal of Affective Disorders · doi:10.1016/0165-0327(80)90029-4 · Cited by 112
Long-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder
Sanger, T. M., Grundy, S. L., Gibson, P. J., Namjoshi, M. A., Greaney, M. G., & Tohen, M. F. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0410 · Cited by 99
Inoue, T., Domae, M., Yamada, K., & Furukawa, T. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12799-7 · Cited by 92
A meta-analysis of the use of typical antipsychotic agents in bipolar disorder
Tohen, M. F., Zhang, F., Taylor, C. C., Burns, P., Zarate, C. A., Sanger, T. M., & Tollefson, G. D. (2001) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00162-2 · Cited by 82
A review of randomized, controlled clinical trials in acute mania
Keck, P. E., Mendlwicz, J., Calabrese, J. R., FAWCETT, J. A., Suppes, T. M., Vestergaard, P., & Carbonell, C. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(00)00177-4 · Cited by 59
Self-citationNew treatments for bipolar disorder: the role of atypical neuroleptic agents.
Ghaemi, S. N. (2000) · PubMed · Cited by 45
Treatment and prevention of mania: a Scandinavian perspective.
Vestergaard, P. (1992) · PubMed · Cited by 42
Cited by
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300203 · Cited by 968
Yatham, L. N., Kennedy, S. H., Schaffer, A., Parikh, S. V., Beaulieu, S., O'Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., Ravindran, A., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00672.x · Cited by 570
Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis
Bak, M., Fransen, A., Janssen, J., van Os, J., & Drukker, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094112 · Cited by 490
“1999 [62–68]; 2000 [69–73]; 2001 [74–90]; 2002 [37,91–106]; 2003 [107–132]; 2004 [133–157]; 2005 [158–191]; 2006 [46,192– 218]; 2007 [219–254]; 2008 [45,49,255–286]; 2009 [287–317]; 2010 [43,318–338]; 2011 [50,339–359]”
Metadata
- Authors
- Keck, P. E., Marcus, R., Tourkodimitris, S., Ali, M., Liebeskind, A., Saha, A., Ingenito, G., & Aripiprazole Study Group
- Venue
- American Journal of Psychiatry
- Published
- 2003-09-01
- Volume
- 160
- Issue
- 9
- Pages
- 1651-1658
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2095635647
- Cited by
- 501
- References
- 32
- FWCI
- 25.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.